Drugs / CHF10196
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07683793 | Oct → Dec 2026 expected | — | Chiesi Farmaceutici S.p.A. | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07577804 | Nov 2026 → Apr 2030 expected | bronchiectasis | Chiesi Farmaceutici S.p.A. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHF10196 | “A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants” NCT07683793 ↗ |
| Known as | florensocatib | “A Study to Compare How CHF10196 (Florensocatib) is Absorbed Into the Blood When Given Alone and With a Drug That Reduces Stomach Acid in Healthy Male Participants” NCT07683793 ↗1“CHF10196 tablets (florensocatib)” NCT07577804 ↗ |